Andere talen NexImmune, Inc.

Aandelen

Vertraagde tijd Nasdaq Andere beurzen 20:52:29 23-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
3,58 ^USD	-1,78%		+3,17%	+61,26%

16/04	NexImmune, Inc. rapporteert resultaten voor het volledige jaar eindigend op 31 december 2023	CI
05/04	NexImmune, Inc. kondigt wijzigingen aan in de leiding	CI

North American Morning Briefing : Stock Futures -2-	17/04
NexImmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16/04
North American Morning Briefing : Traders Await -2-	10/04
NexImmune, Inc. Announces CFO Changes	05/04
NexImmune, Inc. Announces Executive Changes	05/04
North American Morning Briefing : Powell Awaited -2-	03/04
NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	02/02
Bull Run 2024: Biopharma Healthcare Stocks Surge, Gaining Momentum: DYAI, ABVC, FWBI, VTAK, NEXI	08/01
Top Premarket Decliners	04/01
Top Premarket Decliners	04/12
Neximmune : Failure to Satisfy Listing Rule - Form 8-K	01/12
Wall Street Set to Open Lower Friday as Investors Await Economic Data, Powell Speech	01/12
Top Premarket Gainers	01/12
Investors Look Ahead to Powell Speech as US Futures Trend Lower Friday	01/12
North American Morning Briefing : Stocks Futures -2-	20/11
NexImmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	17/11
Top Premarket Decliners	06/11
Top Premarket Decliners	03/11
NexImmune Extends Partnership With Yale, JDRF for Type 1 Diabetes	24-10-23
NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes	24-10-23

Geen resultaten voor deze zoekopdracht